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ABSTRACT
Objective: The present study aimed to evaluate the role of crude extract and phytosterol fraction of Fumaria officinalis in experimentally induced 
hypertrophic scar in rabbits.
Methods: Surgical wounds were performed on day 1 with an 8‑mm biopsy punch four wounds were created on the ventral surface of the rabbit 
ear (in vivo) down to cartilage. Triamcinolone acetonide (TAC), crude and phytosterol extracts of F. officinalis L. are administered topically to 
established scars on day 31. The outcome measures included study of histopathology of skin sections, transforming growth factor beta‑1 (TGF‑β1), 
level, and collagen three alpha1 in skin tissue.
Results: In comparison with the induced hypertrophic scar, all treatment produced a significant reduction in scores of TGFβ1, collagen III, 
inflammation, and measurement of SEI (p ≤ 0.01). The most significant reduction in inflammation and thickness observed in TAC and extract of crude 
F. officinalis L. Only crude F. officinalis L. decrease fibroblast counts in comparison to induced hypertrophic scar group and other group (p ≤ 0.05). No 
statistically significant differences were found between the treatment groups in terms of TGF β1and collagen III.
Conclusion: Topical crude extract of F. officinalis L. was more effective in the treatment of induced hypertrophic scar as compared with phytosterol of 
F. officinalis L. and comparable to the effectiveness of topical TAC.
Keywords: Hypertrophic scar, Rabbit ear model, SEI, Collagen I.
INTRODUCTION
Hypertrophic scars are fibroproliferative disorders that result from 
abnormal wound healing, defined as increased or decreased regulation 
of specific wound healing processes [1]. It is raised, red, rigid, and 
responsible for severe functional and cosmetic problems, primarily 
contain collagen type III orientated parallel to the epidermal surface 
with abundant collagen nodules [2]. Furthermore, nodular structures 
in which alpha‑smooth muscle actin ‑ expressing myofibroblasts, 
small vessels, are present characterize hypertrophic scars [3]. 
Pathological scarring is a significant post‑operative complication that 
is difficult to predict and prevent [4]. Each year in the developed world, 
approximately 100 million people suffer from scar‑related tissues [5]. 
The incidence of hypertrophic scarring has varied in studies between 
32% and 67% rises to 75% in children, young adults and those with 
pigmented skin [6] and up to 91% following burn injury, depending 
on the depth of the wound [2]. The underlying mechanisms of scar 
formation are complicated, and the process may be affected by multiple 
factors [7]. The physiologic response to wounding in adult tissue is the 
formation of a scar, a process that can be temporally grouped into three 
distinct phases: Inflammation, proliferation, and remodeling [8]. Within 
these stages, which often overlap, there are numerous interactions 
between fibrotic and anti‑fibrotic growth factors, cells, extracellular 
matrix (ECM) components, and various enzymes [9]. To date, a number 
of signaling pathways have been implicated in the pathogenesis of 
hypertrophic scar; TGF‑β is a family of growth factors considered to be 
the master regulator of fibrosis and its effects on collagen deposition, 
cell proliferation, immune modulation, apoptosis, differentiation, and 
several other processes have been well established in hypertrophic 
scar [10]. The three isoforms of TGF‑β (TGF‑β1, ‑β2, and ‑β3) are 
secreted as inactive latent precursors that require activation before 
binding to the TGF‑β receptors [11]. There appears to be an alteration 
in TGF‑β signaling (through increased phosphorylation of the receptor 
SMAD proteins) in hypertrophic‑derived fibroblasts and a decreased 
expression of the inhibitory SMAD 7 in hypertrophic scar‑derived 
fibroblasts [12]. The majority of cells involved in wound healing 
express TGF‑β in an inactive form that actively promotes the chemotaxis 
of fibroblasts to the site of injury [3]. Fibroblasts derived from 
hypertrophic scars have demonstrated both an increased expression of 
the pro‑fibrotic cytokine, transforming growth factor beta 1 (TGF‑β1), 
and prolonged feeling of the associated TGF‑β receptors [13]. This study 
aimed to investigate our hypothesis that crude extract and phytosterol 
fraction of Fumaria officinalis may be successful in the therapeutic 
modulation of scar formation in vivo.
The genus Fumaria L. (Fumariaceae) consists of 60 species widely 
distributed all over the world [14]. F. officinalis L. is an annual herbaceous 
plant, the medicinal parts are represented by the dried aerial parts 
harvested during flowering [15]. This herb is a component of several 
phytopharmaceuticals, mainly used to treat functional diseases of the 
hepatobiliary system discernible as colicky pains affecting the gallbladder, 
biliary system, and gastrointestinal tract [16]. Fumaria also used to 
treat chronic eczema, cutaneous eruptions, and other dermatological 
circumstances [17]. The fumaric acid esters have used as an action for 
psoriasis for nearly 30 years [18]. Studies showed significant antioxidant 
activity in vitro; nevertheless, that is not known whether it is equally 
effective in vivo [19]. This management is giving us interesting to apply 
this compound in the current study. On the other hand, phytosterol is a 
large group of compounds that are found exclusively in plants. They are 
structurally related to cholesterol and have cholesterol reduction effect 
and prevention against certain types of cancer such as colon, breast, and 
prostate [20], and also stimulation of immunity and protection of skin [21].
METHODS
A total of 48 healthy male albino rabbits between 6 and 12 months of 
age were used in the study. Before starting the work, the animals were 
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left for 48 h to acclimatize to the animal room conditions of controlled 
temperature (28–30°C), allowed free access to water ad libitum and 
food. Protocol of the current research was approved by the Institute 
Review Board Al‑Nahrain University College of Medicine. Rabbits 
described hypertrophic scar model were anesthetized with (IM) 
injection of ketamine (45 mg/kg) and xylazine (5 mg/kg). Surgical 
wounds were performed on day 1 with an 8‑mm biopsy punch. Four 
injuries were created meticulously on the ventral surface of one 
ear down to cartilage. Removal of the perichondrial layer delayed 
epithelization after the hemostasis has been achieved with manual 
pressure; wounds were covered with sterile gauze for 1 day. On day 30, 
and the eventual scars were obtained.
Plant material
The herb included in this study was identified and authenticated in 
the Pharmacognosy Department, College of Pharmacy, University of 
Baghdad, Iraq.
Preparation of extracts
Powder from aerial parts of F. officinalis (250 mg) was extracted with 
90% ethanol (600 ml) in reflex apparatus until complete exhaustion 
and evaporation to give crude fraction. Crude extract was acidified with 
hydrochloric acid (5%) at pH 2 then partitioned with equal volume of 
ethyl acetate to give two layers (aqueous and ethyl acetate) layer, ethyl 
acetate layer was collect, evaporated then basified with 300 ml of sodium 
hydroxide 5%, and extracted with chloroform to get also two layers, 
two types of solvent: methanol 80% and petroleum ether was added to 
chloroform layer to obtain phytosterol in petroleum ether fraction [22].
High‑performance liquid chromatography (HPLC) analysis
The sterol compound of F. officinalis was determined by a Waters 
Germany HPLC system with ODS column (250 mm × 4.6 mm, 5 μm). 
1 mg of sterol fraction was dissolved in 5 ml 70% methanol and 
detected at 210 nm at a flow rate of 1 ml/min. The data were analyzed 
with the phytosterol standards prepared as a solution of three standard 
concentrations of each 0.5 mg/1 ml of standards in methanol and 
performed as a single run in HPLC [23].
Preparation of gels formulations
The concentration of chemical (s) and extract (s) was weighed and 
dissolved in 10 ml of absolute ethanol alcohol to prepare (solution A) 
after that 3 g powder of HPMC was added to the 75 ml of distilled water 
with stirring to get (solution B). Solutions A and B were mixed thoroughly, 
and the final weight was made up to 100 g [24]. All the samples were 
allowed to equilibrate for at least 24 h at room temperature [25].
Treatment groups
The treatment groups are as follows: Group 1 ‑ Healthy animal group; 
Group 2 ‑ hypertrophic scar was induced, and the animals left without 
treatment (only base gel); Group III ‑ rabbits with induced hypertrophic 
scar treated with triamcinolone acetonide (TAC) 0.1% as standard drug; 
Group VI ‑ rabbits with induced hypertrophic scar treated topically 
with crude extract of F. Officinalis L.3%; and Groups V, VI ‑ rabbits 
with induced hypertrophic scar treated with phytosterol extract of 
F. officinalis L. 0.2% and 0.4%, respectively. Dugs and extracts were 
given twice daily for 21 days as formulated topical gel.
Collection of samples
The samples were collected from each animal after anesthetized the 
animals at the end of the experiment (51 days) using 11 mm bunch 
biopsy with more than 3 mm margin of adjacent skin [26] then 
submitted for histological and immunohistochemical analysis.
Preparation of the samples
Each wound sample was stored in 10% formaldehyde solution prepared 
in section to use for histopathological and immunohistochemistry study.
Preparation of formalin‑fixed paraffin‑embedded tissues
Tissue fixation sections transferred into formalin (10%); fixative 
volume was 20 times that of tissue on a weight per volume, tissue was 
fixed for a minimum 48 h at room temperature and then processed, 
using gentle agitation [27], then tissues embedded in paraffin blocks.
Tissue sectioning and slide preparation
Serial sections (3–5 μm) thickness were obtained using microtome, 
from each wound paraffin block, 105 slides were prepared. Sections 
were mounted on ordinary slides (to be used in Hematoxylin and 
Eosin [H&E] staining system) and on positively charged slides (to be 
used for immunohistochemistry) using a water bath of 45°C to prevent 
tissues sections folding during mounting procedure, each slide was 
labeled using a pencil to carry the same number on its paraffin block.
H&E staining of paraffin sections
The Haematoxylin and Eosin staining system were used for 
histopathological examination as desceibed by Anderson et al., (1996) [29].
Assessment of histopathological changes in skin sections
SEI index is the ratio of the highest vertical height of scar area between 
perichondrium and skin surface to the highest vertical height of normal area 
around the scar between perichondrium and skin surface. Each wound was 
measured by a blinded examiner using a calibrated eyepiece reticule [29].
The degree of inflammation and fibroblast counts was evaluated in a 
semi‑quantitative manner. The degree of inflammation was evaluated 
according to the following scores: 0 = none; 1 = mild; 2 = moderate; and 
3 = severe. Fibroblast count was evaluated according to the following scores: 
0 = absence of fibroblasts; 1 = few fibroblasts; 2 = presence of disorganized 
fibroblasts; and 3 = presence of fibroblasts parallel to the wound surface [30].
Immunohistochemistry IHC detection of collagen III, TGFβ1
(I) Anti‑collagen III antibody: Rabbit polyclonal antibody to 
collagen III (Code number: MBS822102) (MyBioSource, USA). (II) 
Anti‑TGFβ1antibody: Rabbit polyclonal antibody to TGFβ1 (Code 
number: ab190503) (Abcam, UK).
Immunohistochemistry IHC procedure:
Five μm thick sections were made on positively charged slides, and 
the staining procedure was perform as in manufacture protocol, using 
ab80436 staining kit. Immunohistochemistry kits for detection of 
collagen 3 alpha1, TGF‑β1.
EVALUATION OF IHC RESULTS
Quantification of TGF‑β1 and collagen protein expression was evaluated 
under light microscopy at X20. The extent of the immunohistochemical 
reaction of ECM proteins, such as collagen, was measured by ranking the 
signal intensities according to the following scale: – (absent), + (mild), 
++ (moderate), and +++ (marked) [31]. Stained slides were examined 
to identify immunoreactivity for TGF‑β1. Scoring system was done, and 
the score recorded was the average intensity of the expression: Absence 
of immunoreactivity had score 0, weak immunoreactivity had score1, 
moderate immunoreactivity had score 2; and strong immunoreactivity 
had score 3 [32].
Statistical analysis
Data were collected, summarized, analyzed, and presented using two 
statistical software programs: The statistical package for the social 
sciences (SPSS version 22) and Microsoft Office Excel 2013. All results 
are presented as means ± SD. Comparison of mean values between 
the two groups was carried out using the Mann–Whitney U‑test and 
unpaired t‑test. Data for multiple comparisons were performed by 
Kruskal–Wallis test, post hoc Tukey test, and one‑way ANOVA. P ≤ 0.05 
was considered significant and highly significant when P ≤ 0.01 [33].
RESULTS
Healing rate
Appearance of untreated induced hypertrophic scar
Normal healing process involves three overlapping phases: 
Inflammation (0–3 days), cellular proliferation (3–12 days), and 
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remodeling (3–6 months), so in this group there is inflammatory signs 
seen from the 1st day in all animals with partial wound closure starting 
from the 4th day and excessive formation of fibrosis (100% induction) at 
30th day as shown in Figure 1.
Group III (induced hypertrophic scar in rabbits treated with 
triamcinolone acetonide): Healing signs were very clear starting after 
treatment with fading of the inflammatory sign. Finally, complete 
wound closure and decrease thickness of scar (after 21 days of 
treatment) Figure 2a.
Group IV (induced hypertrophic scar in rabbits treated with crude 
F. officinalis) Figure 2b: Remarkable decrease of inflammatory signs 
occurred after starting treatment with the closure of the wound and no 
sign of thickness after 21 days of treatment.
Group V (induced hypertrophic scar in rabbits treated with 0.2% 
phytosterol fraction of F. officinalis): This group showed a gradual 
decrease of the inflammatory sign with the close of the wound and a 
moderate reduction of thickness after 21 days of treatment Figure 2c.
Group VI (induced hypertrophic scar in rabbits treated with 0.4% 
phytosterol fraction of F. officinalis): Healing signs were very clear 
starting after treatment with fading of the inflammatory sign. Finally, 
complete wound closure and decrease thickness of scar after 21 days 
of treatment Figure 2d.
IMMUNOHISTOCHEMICAL RESULTS
Immunohistochemical for TGF‑β1 and collagen III is shown in Table 1, 
Figures 3 and 4. There was an extremely high significant difference 
in mean of immunohistochemical scores of TGF‑β and collagen III 
between healthy control and induced hypertrophic scar group enrolled 
in the present study (p ≤ 0.001).
All treatment groups showed a highly significant reduction in IHC 
expression scores of TGF‑β and collagen III (p ≤ 0.01) as compared 
to induced hypertrophic scar. No significant variation in TGF‑β1 and 
collagen III marker was observed between groups (p > 0.05) as shown 
in Table 2 and Figure 5.
Histological results
Histopathological score reflective of scar in experimentally 
induced hypertrophic scar was shown to be extremely high 
significant (p ≤ 0.001) increased in the induced hypertrophic group 
without treatment in comparsion to the healthy control group as show 
in Table 3 and Figure 6. All treatment groups produced a significant 
reduction in inflammatory in comparison with induced hypertrophic 
scar group (p ≤ 0.001). Highly significant reduction was observed in scar 
elevation index of TAC, extract of F. officinalis L. and both concentration 
of 0.4% and 0.2% of phytosterol extract of F. officinalis L., respectively, 
as compared with induced hypertrophic scar (p ≤ 0.01).The only crude 
extract of F. officinalis L. produced a significant reduction of fibroblast 
count in comparison to induced hypertrophic scar group and another 
group (p = 0.002). Both TAC and crude extract of F. officinalis L. 
produced the most significant reduction in inflammation and thickness 
of hypertrophic scar as compared to other treatment groups. All results 
are shown in Tables 3 and 4, Figures 6‑9.
Figure 2: The application and effect of treatment groups after 21 days (a) Triamcinolone acetonide, (b) Crude Fumaria officinalis, (c) 0.4% 
phytosterol, (d) 0.2% phytosterol
a b
c d
Figure 1: (a and b) Gross morphological features of healing rate in 
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HPLC
Retention time of three sterols fraction was shown in Table 5 and 
Figure 10. Scanning profile of 90% hydroalcoholic extract of phytosterol 
fraction of f. officinalis L.in HPLC method showed β‑sitosterol at RT 4.9, 
stigmasterol at RT 5.3 and campesterol at RT at 2.7.
DISCUSSION
Hypertrophic scars are a complex pathologic process which 
characterized by proliferation of the dermal tissue, excessive 
deposition of fibroblast‑derived ECM over a prolonged period and 
persistent inflammation and fibrosis [34]. Such pathological scarring 
can lead to severe functional impairment, psychological morbidity, 
and costly long term health care [35]. The treatment for HS remains 
a difficult problem to prevent and treat [36], which is embodied in 
several aspects as follows: (1) The treatment time is too long, (2) lack 
of specific remedies, various management must join to apply, which are 
still not so much useful for the scar disease, (3) several drugs have side 
effects, leading to the limit of dosage and cure time, and (4) the lack 
of early interventions may deprive the optimal time for treating [37] 
for this reasons hypertrophic scar make a strong stimulus to find out a 
new relatively safe and effective modality of treatment which may serve 
as the early intervention to treat HS more effectively or intensify the 
function of corticosteroids and chemotherapeutic agents. The rabbit 
dermal model was used and validated in a variety of studies evaluating 
the effect of age on scars, molecular mechanisms agents, and efficacy of 
therapeutics [38].
TGF‑β can mediate fibroblast proliferation, angiogenesis, ECM synthesis, 
and re‑epi thelialization in the wound‑healing process [39]. On the 
other hand, it was demonstrated that fibrogenic response to injury is 
mediated through angiotensin II induction of TGF‑β1 expression [40]. 
Particularly, TGF‑β1 transcriptionally regulates various fibrosis‑related 
proteins, including Type I and III collagens [41]. It can also promote 
the transformation of fibroblasts to myofibroblasts, which are the 
significant cells contributing to HS formation and characterized by an 
increased synthesize collagen and up regula tion of cytokines [42]. In the 
current study, the rabbit ear hypertrophic scar model was successful as 
there were significant differences between induced hypertrophic scar 
and healthy skin in cellular response to growth factors (TGF‑β) which is 
consistent with the finding of Kim et al. 2015 [43].
Topical TAC in this study caused significant reduction of TGF‑β1 
as compared to induced scar non‑treated group after 21 days of 
treatment (p ≤ 0.05) that is in accordance with Sari et al.[44] which 
found significant differences of pro‑inflammatory cytokines TGF‑β1 
and collagen III in rabbit ear model after treatment with topical TAC.
Regarding F. officinalis, there no previous reports on the effect of 
Fumaria on hypertrophic scar which refer to the novelty of the current 
study. Crude ethanolic extract prepared from aerial parts of the 
Table 1: Mean of TGF‑β1and collagen III in the control and study groups
Parameters G1 n=8 G2 n=8 G3 n=8 G4 n=8 G5 n=8 G6 n=8
TGF‑β1
Mean±SD 1.13±0.35 3.0±0.0 2.0±0.54 1.38±0.74 1.5±0.54 1.75±0.46
p value <0.001 0.002* 0.002* <0.001* <0.001*
Collagen III
Mean±SD 1.0±0.0 3.0±0.0 2.13±0.64 1.5±0.76 1.5±0.54 1.63±0.52
p value <0.001 0.010* 0.002* <0.001* <0.001*
Mann–Whitney U‑test. SD standard deviation; p indicates the level of significance at p≤0.05; *Indicate a comparison between induced hypertrophic scar and another 
group. (G1) Healthy control, (G2) Induced hypertrophic scar, (G3) TA steroid, (G4) crude FO, (G5) phytosterol 0.2%, (G6) phytosterol 0.4%. TGF‑β1: Transforming 
growth factor‑beta 1
Figure 3: Mean transforming growth factor‑beta 1 (TGF‑β1) scores 
in the control and study groups. (G1) Healthy control,(G2) induced 
hypertrophic scar, (G3) TA steroid, (G4) crude FO, (G5) phytosterol 
0.2%, (G6) phytosterol 0.4%
Figure 4: Mean collagen III scores in the control and study 
groups. (G1) healthy control, (G2) induced hypertrophic 
scar, (G3) triamcinolone acetonide steroid, (G4) crude FO, (G5) 
phytoserol 0.2%, (G6) phytoserol 0.4%
Table 2: Immunohistochemical comparison between study 
groups in TGFβ1 COLIIIαI
Parameters G3 n=8 G4 n=8 G5 n=8 G6 n=8 p value
TGFβ1
Mean±SD 2.0±0.54 1.38±0.74 1.5±0.54 1.75±0.46 0.157
COLIII
Mean±SD 2.13±0.64 1.5±0.76 1.5±0.54 1.63±0.52 0.132
Kruskal–Wallis test SD: Standard deviation; p indicates the level of significance 
at p≤0.05; n: Number of animals, G3 TA steroid, G4 crude FO, G5 phytosterol 
0.2% and G6 phytoserol 0.4. (G1) healthy control, (G2) Induced hypertrophic 
scar, (G3) TA steroid, (G4) crude FO, (G5) phytosterol 0.2%, (G6) phytosterol 
0.4%. COLIIIαI: Collagen 3 alpha1
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plant and phytosterol fraction caused significant reduction of TGF‑β 
with a slight difference in reduction of TGF‑β1 between two doses of 
phytosterol topical gel. Three phytosterols: β‑sitosterol, campesterol 
was identified by HPLC method.
The result of the current study is in agreement with Jurjus et al.[45] that 
studied the effect of MEBO which is composed of beta‑sitosterol 0.25% 
as an active ingredient in the induced burn of the rabbit.
Model and found persistent rise in levels of TGF‑β1 from day 2 to day 
9 then dropping back on days 12 and 15. Furthermore, the reduction 
of TGF β1 in crude F. officinalis L. may be due to Fumaric acid esters 
which were isolated for the 1st time from the plant F. officinalis [46]. 
Ivanov et al. in[47] discussed chemical constituent in 5 fumaria 
species (Fumariaceae) and found the highest phenolic content such as 
quercetin, p‑coumaric, and ferulic acids in the extract of F. oficinalis; 
this compound has antioxidant activity, anti‑inflammatory, and 
anti‑proliferative effects [48,49]. Triamcinolone acetonide, F. officinalis 
L. and its fraction of phytosterol in two doses were effective in reduction 
immunohistochemical marker of TGF‑β1, and no difference between 
them was observed. In terms of collagen III, the result of the current 
study proves the elevation of this biomarker in induced hypertrophic 
scar group, which is consistence with the finding of Oliveira 
et al. [50]. Research also showed significant reduction of collagen III 
in TAC group as compared to untreated induced scar after 21 days of 
treatment (p ≤ 0.05) that is in agreement with the findings of Uzun et al. 
in 2013 [51].
Crude F. officinalis L. and both concentration of phytosterol extract (0.2%, 
0.4%) showed a significant decrease in collagen III with more reduction 
was observed in a lower dose of phytosterol topical gel; this finding is 
in accordance with Rizvi et al. [52] that demonstrated the significant 
effect of Fumaria parviflora leaves in reduce the number of fibroblasts, 
synthesis of collagen and mucopolysaccharide of cotton pellet‑induced 
granuloma in rats after 7 days treatment. F. officinalis affect ECM 
structure of the dermis layer due to inhibition of pro‑inflammatory 
cytokine TNFα, interleukin (IL)‑6, and anti‑inflammatory cytokine 
IL‑1 that consider powerful chemotactic agents for macrophages and 
fibroblasts proliferation [53]. Triamcinolone acetonide, F. officinalis L. 
and its fraction of phytosterol in two doses were effective in reduction 
immunohistochemical marker of collagen III and no difference between 
them was observed. Hypertrophic scar differs from the normal wound 
healing process in an inflammatory response with increasing cellular 
migration, proliferation, matrix deposition, and tissue remodeling. 
Table 3: Mean of histological outcome in the control and study groups
Parameters G1 n=8 G2 n=8 G3 n=8 G4 n=8 G5 n=8 G6 n=8
Fibroblast count
Mean±SD 0.0±0.0 2.0±0.0 2.25±0.46 2.88±0.35 2.25±0.46 2.5±0.54
p value <0.001 0.442* 0.002* 0.442* 0.105*
Inflammation
Mean±SD 0.0±0.0 2.75±0.46 0.75±0.46 0.75±0.46 1.88±0.35 1.13±0.35
p value <0.001 <0.001* <0.001* <0.001* <0.001*
Scar elevation index
Mean±SD 1.0±0.0 8.03±0.87 3.03±0.42 3.94±1.11 5.97±1.54 4.4±1.59
p value <0.001 <0.001* <0.001* 0.005* <0.001*
Unpaired t‑test, Mann–Whitney U‑test. SD standard deviation; p indicates the level of significance at p≤0.05; *Indicate a comparison between induced hypertrophic scar 
and another group. (G1) healthy control, (G2) induced hypertrophic scar, (G3) TA steroid, (G4) crude FO, (G5) phytosterol 0.2%, (G6) phytosterol 0.4%
Figure 5: Cytoplasmic immunohistochemically expression of transforming growth factor‑beta 1 (TGF‑β1) and extracellular 
immunohistochemically expression of collagen III of treatment groups (×20). (a and b) Hypertrophic scar showed moderate intensity 
TGF‑β1 and collagen 3 (COLIII) in triamcinolone acetonide‑treated group and 0.4% phytosterol treated group, respectively (c and d). 
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The present work demonstrated characteristic histological changes in 
the untreated hypertrophic scar, radically increase in fibroblast count, 
inflammation degree, and index of the scar. Regarding inflammation, 
the current study showed that triamcinolone acetonide significantly 
reduced the infiltration of inflammatory cell induced by punch biopsy 
in rabbit ear model.
Pessoa et al. [54] described the anti‑inflammation activity of 
triamcinolone acetonide after 14 days’ treatment in the wound of 
rats’ model and registered nearly same observation of our results. 
In part of herb, aerial part of crude F. officinalis possesses marked 
anti‑inflammatory effect while phytosterol fraction of F. officinalis 
showed dose depended on anti‑inflammation with higher significant 
decrease observed at the dose of 0.4% then 0.2% of a topical 
gel. This finding agrees with Rizvi et al. [52] that documented 
the anti‑inflammatory activity and scavenging effect of leaves of 
F. parviflora through inhibition of various cytokines in rats. Phytosterols 
of F. officinalis L. have anti‑inflammatory action [21], anti‑inflammatory 
of F. officinalis L. can also relate to various phytochemicals such as 
isoquinoline alkaloids (fumaric acid), phenolic compounds, and 
flavonoid [55]. Crude F. officinalis L. is comparable to TAC as both have 
been shown the most anti‑inflammation effect in this study.
On the other hand, results of fibroblast count showing the following, 
TAC exhibited an insignificant change in the presence and organization 
of fibroblast in the experimentally induced hypertrophic scar, this 
finding agrees with the observation of Çaliskan et al. in 2016 [56]. Crude 
F. officinalis L. produced a significant reduction of fibroblast count while 
phytosterol fraction of 0.2% and 0.4% showed insignificant alteration 
in fibroblast count. The effect of phytosterol on decrease proliferation 
of fibroblast is dose depended as 0.4% topical gel produced more 
reduction in this finding.
Which is agree with Capistrano et al. in 2015 [57] that identified 
alkaloid (protopine and Sanguinarine) of Chelidonium majus 
L. (Papaveraceae) and detected the significant cytotoxic activity of this 
alkaloid against both in vitro human pancreatic cell line and murine of 
same cell line at a dose of 1.2mg after IP injection for 3 days?
SEI is obtained with the measurement of highest vertical height 
from perichondrium to epidermal surface in scar area and normal 
tissue around the scar. TAC (standard drug) was shown a significant 
decrease in the measurement of SEI that agrees with Çaliskan 
et al. [56]. Regarding herb, crude F. officinalis L. and phytosterol 
extract of (0.2% and 0.4%) established a significant reduction 
of index of scar with extreme reduction were observed in crude 
F. officinalis L. and high dose of phytosterol this results is disagreeing 
with Saulis et al. [29] that detected an insignificant decrease in scar 
index after 4 weeks’ treatment with onion extract in rabbits ear 
model.
Table 4: Comparison of histological parameters between every 
pair of study groups
Dependent variable 1st group 2nd group p value
Fibroblast count G4 G3 0.038
G5
Inflammatory degree G5 G3 0.001
G4
G6 0.010
Scar elevation index G5 G3 0.016
G4
Kruskal–Wallis test post hoc Tukey test indicates the level of significance 
at p≤0.05, (G3) TAC steroid, (G4), crude FO,(G5) phytosterol 0.2%, (G6) 
phytosterol 0.4%. TAC: Triamcinolone acetonide
Table 5: Retention time of phytosterol compounds




Figure 6: Mean of inflammation score in control and study 
groups (G1) healthy control, (G2) induced hypertrophic scar, (G3) 
triamcinolone acetonide steroid, (G4) crude FO, (G5) phytosterol 
0.2%, (G6) phytosterol 0. 4%
Figure 7: Mean of scar elevation index in control and study 
group. (G1) healthy control, (G2) induced hypertrophic 
scar, (G3) TA steroid, (G4) crude FO, (G5) phytosterol 
0.2%, (G6) phytosterol 0.4%
Figure 8: Mean of fibroblast count of control and study 
group (G1) healthy control, (G2) induced hypertrophic 
scar, (G3) triamcinolone acetonide steroid, (G4) crude 
FO, (G5) phytosterol 0.2%, (G6) phytosterol 0.4%
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Two groups were the diminishing thickness of hypertrophic scar due to 
net beneficial effect in the process of wound healing includes TAC and 
crude F. officinlis L.
CONCLUSION
The crude extract of F. officinalis seems to be more effective in reducing scar 
in compared to phytosterol extract of F. officinalis and comparable to TAC.
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